Gsk Share Discussion Threads

[philanderer] 21/11/2017 10:43

Thank goodness for that :-)

[mj19] 21/11/2017 10:27

That's what I wanted to hear lol

[woodhawk] 21/11/2017 10:11

We haven't started another wave down.

[mj19] 21/11/2017 10:05

Please tell me we haven't started another wave down

[philanderer] 21/11/2017 09:38

Concordia....can of worms opened by..


'NHS overcharged by millions for key drug, says watchdog'

[tradermichael] 21/11/2017 09:35

Next xd is end of February, 23p per share ....;0)

[woodhawk] 21/11/2017 09:34

Just topped up at 1300p. Lovely.

[essentialinvestor] 21/11/2017 09:31

Surprised sub 13 was not sooner.

So how low can we go...?

[kemorkid] 21/11/2017 09:24

When are they xd

[montyhedge] 21/11/2017 09:23

Witty left at the right time it seems.

[fangorn2] 21/11/2017 09:10

Sub 1300p - seriously.

Wow, Emma has been a disaster for this company's share price.

[ianood] 20/11/2017 20:30

Ironic that, drugs and drugs centre!

[alphorn] 20/11/2017 17:43

The EU27 have chosen Amsterdam as the city that will host the European Medicines Agency when it leaves London after Brexit.

[mj19] 19/11/2017 16:43

Today's favouriteThe one that really has been catching my eye lately is GlaxoSmithKline (LSE: GSK). I've been following Glaxo for a few years now. That's ever since earnings growth at the pharmaceuticals giant went into reverse when the firm was hit by the expiry of some key best-selling drugs and by increasing competition from generic alternatives. AstraZeneca suffered similarly and the two have been pursuing a programme of beefing up their drug pipelines.The corner now seems to have been turned by Glaxo, as the company reported a 35% rise in earnings per share last year. But a slowdown to a forecast of 8% growth this year followed by a 2% shrinkage in 2018 and fears of a dividend cut appear to turned investors away, and the shares have slipped in value to 1,314p.We're looking at a forward P/E multiple based on 2017 forecasts of only 12 - and with long-term growth potential, I reckon it deserves a rating in excess of the long-term FTSE 100 average, which stands at around 14.And Glaxo's dividend, which has been maintained at 80p per share throughout the downturn, is currently set to yield 6%, which is around twice the FTSE 100 average.Third quarterAt Q3 time, chief executive Emma Walmsley spoke of "sales growth and improved operating margins," after new product sales rose by 40% to £1.7bn. I think that's quite impressive at this stage, after a quarter that saw total sales of £7.8bn, as it's laying the foundations for profits from the company's next generation of products.And we're seeing a constant stream of development progress, with the company's new COPD treatment Trelegy Ellipta approved for use in the US and the EU, and its Shingrix shingles vaccine being approved in the US and Canada. A US approval application has also been made for another COPD treatment, mepolizumab, with filings for other markets planned for this year and next.As for the dividend, I'm optimistic and I see improving cash flow as being able to cover good returns over the long term. But even if there's a cut, I'd still expect a decent yield to be maintained - and reinvesting the cash should help boost research and growth.I reckon if you pick Glaxo or AstraZeneca, couple that with BP or Shell, maybe choose a bank if you're not of a nervous disposition, add a dividend-paying energy firm (National Grid would be my choice) and top it off with an insurer (I hold Aviva), you'd have a very sold core portfolio.

[adamb1978] 19/11/2017 14:14

Where do the comment about an uncovered dividend come from? FCF for next year is £5.4bn per consensus estimates whilst the dividend pay-out is around the £4bn mark

[bili1946] 18/11/2017 19:21

We are back to share price of some 10 years ago.I cannot see why this should not continue the drift if the index slips?
I hope I am wrong.

[billionaire1] 18/11/2017 13:28

sub 13 next week?
hopefully not

[sat69] 18/11/2017 00:51

Just updated the 20 year chart folks.

If the dividend is cut I would expect a test of the £10 level as the big fundies will be selling. I will therefore stay clear of this one.

[mj19] 17/11/2017 18:19

Jefferies Has Just Reaffirmed GBX 1450.00 Target Price Per Share on Glaxosmithkline (LON:GSK) stock, While They’ve Also Reiterated Their “Buy” Rating

November 17, 2017 - By Peter Erickson

Glaxosmithkline (LON:GSK) Rating Reaffirmed

The financial firm has just set a target price per share of GBX 1450.00 on Glaxosmithkline (LON:GSK) shares. This is 10.43 % from the current stock price. In a research note revealed to investors on Thursday, 16 November, Jefferies reaffirmed their “Buy” rating on shares of GSK.

a few days before -

9th November 2017 11:40 | GlaxoSmithKline PLC
Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1075p.

Go figure.... so somewhere in between like £12.62 ..... this week and next week some other broker says some stuff... its just stuff no reasons why...how they say stuff without reasons is beyond me.... i could do that job...lol

[mj19] 17/11/2017 18:11

so the focus is that simple...the thing is, the market don’t care yet, they are concerned about dividend growth and debt... and maybe the new ceo lol so we all have to wait and see the new products start bringing in the money....arent you the one who said the share price wouldn't go lower? crystal ball stuff lol

[tradermichael] 17/11/2017 18:00

Stop talking dividends.... this company just launched 2 blockbusters!

[essentialinvestor] 17/11/2017 17:10

Growing UK political risks hanging heavy over utilities.

[mj19] 17/11/2017 17:09

Annoying really as it always can get cheaper...

[atlantic57] 17/11/2017 17:01

Mj forgive me for one post on Ng on this thread but surely that fall is way overdone.

a uk interest rates are unlikely to rise dramatically in the near term

B the dividend is solid

C political risk seems to be discounted